nephropathic cystinosis

US FDA approves Raptor Pharma's Procysbi for treatment of nephropathic cystinosis

US FDA approves Raptor Pharma's Procysbi for treatment of nephropathic cystinosis

Pharmabiz

Raptor's FDA Approval Is New Test For Orphan Drug Pricing

Raptor's FDA Approval Is New Test For Orphan Drug Pricing

TheStreet.com

Why Raptor Could Run Up To Its PDUFA

Why Raptor Could Run Up To Its PDUFA

Seeking Alpha

Raptor To Rise On Proven Strategy & Upcoming FDA Decision

Raptor To Rise On Proven Strategy & Upcoming FDA Decision

Seeking Alpha

Raptor Drug FDA Action Date Delayed

Raptor Drug FDA Action Date Delayed

Yahoo/Zacks

Raptor Pharma Says FDA Extends PROCYSBI NDA Review By 3 Months

Raptor Pharma Says FDA Extends PROCYSBI NDA Review By 3 Months

NASDAQ

Raptor Pharmaceuticals announces positive data on RP103 extension study

Raptor Pharmaceuticals announces positive data on RP103 extension study

The Fly on the Wall

Raptor Pharma Rises as FDA Starts Drug Review

Raptor Pharma Rises as FDA Starts Drug Review

PharmPro

Raptor Pharmaceutical Corp. Submits New Drug Application for RP103 for the Potential Treatment of Nephropathic Cystinosis

Raptor Pharmaceutical Corp. Submits New Drug Application for RP103 for the Potential Treatment of Nephropathic Cystinosis

Pipeline Review

Raptor Pharmaceuticals: Pipeline Worth a Closer Look

Raptor Pharmaceuticals: Pipeline Worth a Closer Look

Seeking Alpha